A candidate vaccine against malaria has been shown to almost halve the number of malaria cases in young children but only to reduce cases by a quarter in infants. The effectiveness of …
Throughout the covid-19 pandemic, global health scientists and professionals worried not only about this new and emerging viral infection but also about a potential diversion of …
A phase III trial showed that the RTS, S vaccine, which acts against Plasmodium falciparum, had an efficacy of around 30%. 1 The vaccine, which is most effective in children aged …
The study included 6537 infants aged 6-12 weeks and 8922 children aged 5-17 months who were enrolled at 11 centres in seven countries across sub-Saharan Africa. They were …
“This second vaccine holds real potential to close the huge demand-and-supply gap,” said WHO's regional director for Africa, Matshidiso Moeti.“Delivered to scale and rolled out …
The World Health Organization has recommended widespread use of the RTS, S malaria vaccine among children in sub-Saharan Africa and other areas with moderate to high …
The efficacy of the vaccine RTS, S/AS01 in infants aged 6-12 weeks against clinical and severe malaria was 31% and 37%, respectively, found the study, published in the New …
Manufactured by the Serum Institute of India, the R21/Matrix-M malaria vaccine contains the circumsporozoite protein, secreted by the malaria parasite, fused to hepatitis B surface …
An antimalaria vaccine halved the number of first clinical episodes of malaria and severe malaria in children in the 12 months after vaccination, according to results from a clinical …